Literature DB >> 20368392

Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.

Nicolas Grégoire1, Sophie Raherison, Claire Grignon, Emmanuelle Comets, Manuella Marliat, Marie-Cécile Ploy, William Couet.   

Abstract

The objective of this study was to implement a semimechanistic pharmacokinetic-pharmacodynamic (PK-PD) model to describe the effects of ciprofloxacin against Pseudomonas aeruginosa in vitro. Time-kill curves were generated with an initial inoculum close to 5 x 10(6)CFU/ml of P. aeruginosa PAO1 and constant ciprofloxacin concentrations between 0.12 and 4.0 microg/ml (corresponding to 0.5x and 16x MIC). To support the model, phenotypic experiments were conducted with the PAO7H mutant strain, which overexpresses the MexEF OprN efflux pump and phenyl arginine beta-naphthylamide (PAbetaN), a known efflux inhibitor of main Mex multidrug efflux systems. A population approach was used for parameter estimation. At subinhibitory ciprofloxacin concentrations (0.12 and 0.25 microg/ml), an initial CFU decay followed by regrowth was observed, attesting to rapid emergence of bacteria with increased but moderate resistance (8-fold increase of MIC). This phenomenon was mainly due to an overexpression of the Mex protein efflux pumps, as shown by a 16-fold diminution of the MIC in the presence of PAbetaN in these strains with low-level resistance. A PK-PD model with adaptation development was successfully used to describe these data. However, additional experiments are required to validate the robustness of this model after longer exposure periods and multiple dosing regimens, as well as in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368392      PMCID: PMC2876392          DOI: 10.1128/AAC.01478-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).

Authors:  T U Anthony; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Bacterial persistence as a phenotypic switch.

Authors:  Nathalie Q Balaban; Jack Merrin; Remy Chait; Lukasz Kowalik; Stanislas Leibler
Journal:  Science       Date:  2004-08-12       Impact factor: 47.728

3.  Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  Philip Chung; Patrick J McNamara; Jeffrey J Campion; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

5.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  Modelling time-kill studies to discern the pharmacodynamics of meropenem.

Authors:  Vincent H Tam; Amy N Schilling; Michael Nikolaou
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

7.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

8.  Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.

Authors:  Jane Kriengkauykiat; Edith Porter; Olga Lomovskaya; Annie Wong-Beringer
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

9.  A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa.

Authors:  Narcisa Mesaros; Youri Glupczynski; Laëtitia Avrain; Nancy E Caceres; Paul M Tulkens; Françoise Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2007-02-08       Impact factor: 5.790

10.  Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Authors:  M D Maciá; N Borrell; M Segura; C Gómez; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more
  13 in total

1.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

2.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

4.  Effect of Ciprofloxacin, Levofloxacin, and Ofloxacin on Pseudomonas aeruginosa: A case control study with time kill curve analysis.

Authors:  Tiar Sondang Uli Sihotang; Agung Dwi Wahyu Widodo; Pepy Dwi Endraswari
Journal:  Ann Med Surg (Lond)       Date:  2022-09-16

Review 5.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

6.  Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.

Authors:  Soon-Ee Cheah; Jian Li; Brian T Tsuji; Alan Forrest; Jürgen B Bulitta; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  Dayang Fredalina Basri; Lee Wee Xian; Nur Indah Abdul Shukor; Jalifah Latip
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

8.  Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling.

Authors:  Matthieu Jacobs; Nicolas Grégoire; William Couet; Jurgen B Bulitta
Journal:  PLoS Comput Biol       Date:  2016-03-11       Impact factor: 4.475

9.  Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in Pseudomonas aeruginosa PAO1 biofilms.

Authors:  Peter Alexander Vistar Gade; Terkel Bo Olsen; Peter Østrup Jensen; Mette Kolpen; Niels Høiby; Kaj-Åge Henneberg; Thomas Sams
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

Review 10.  Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature.

Authors:  Carly Ching; Ebiowei S F Orubu; Indorica Sutradhar; Veronika J Wirtz; Helen W Boucher; Muhammad H Zaman
Journal:  JAC Antimicrob Resist       Date:  2020-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.